RemeGen nets $515m from Hong Kong IPO

Jonathan Breen

November 04, 2020 09:00 am

Chinese biopharmaceutical firm RemeGen has raised HK$3.99bn ($514.7m) after pricing its IPO at the top of the marketed range, according to a source familiar with the matter.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

JP Morgan Equity IPOs Health and Biotech UBS Equity China Hong Kong SAR Asia Greater China Bank of Communications Haitong Securities Morgan Stanley Northeast Asia Asia Pacific Emerging Markets SRI

JB

Jonathan Breen

Equities editor GlobalCapital Asia